Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
23Andme Holding is a diagnostics & research business based in the US. 23Andme Holding shares (ME) are listed on the NASDAQ and all prices are listed in US Dollars. 23Andme Holding employs 769 staff and has a trailing 12-month revenue of around $248 million.
| Latest market close | $0.46 |
|---|---|
| 52-week range | $0.35 - $2.21 |
| 50-day moving average | $0.53 |
| 200-day moving average | $0.92 |
| Wall St. target price | $1.23 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.11 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.4641 from 2024-04-26
| 1 week (2024-04-19) | -3.89% |
|---|---|
| 1 month (2024-03-27) | -9.07% |
| 3 months (2024-01-26) | -37.96% |
| 6 months (2023-10-27) | -39.66% |
| 1 year (2023-04-27) | -75.31% |
|---|---|
| 2 years (2022-04-27) | -84.63% |
| 3 years (2021-04-27) | 9.98 |
| 5 years (2019-04-23) | N/A |
| Revenue TTM | $248 million |
|---|---|
| Gross profit TTM | $132.9 million |
| Return on assets TTM | -26.17% |
| Return on equity TTM | -92.53% |
| Profit margin | -210.48% |
| Book value | $0.78 |
| Market Capitalization | $238.4 million |
TTM: trailing 12 months
We're not expecting 23Andme Holding to pay a dividend over the next 12 months.
Over the last 12 months, 23Andme Holding's shares have ranged in value from as little as $0.35 up to $2.21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 23Andme Holding's is 1.277. This would suggest that 23Andme Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses.
A deep dive into the highlights and limitations of NinjaTrader.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We rate robo-advisors across eight key categories, including ongoing costs, minimum deposit requirements, portfolio mix and more.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
SoFi is a commission-free platform with both active and automated investment accounts.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn how to buy physical gold and compare gold bullion dealers.